Recruiting
Phase 3

Colchicine

Sponsor:

Population Health Research Institute

Code:

NCT04774159

Conditions

Peripheral Arterial Disease

Atherosclerosis of Extremities

Inflammation

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Colchicine 0.5 MG Oral Tablet

Colchicine-Placebo

Study Details

Brief summary:

The Low dose ColchicinE in pAtients with peripheral Artery DiseasE to address residual vascular Risk (LEADER-PAD) trial will evaluate if anti-inflammatory therapy with colchicine will reduce vascular events in patients with symptomatic peripheral artery disease.

Conditions

Peripheral Arterial Disease

Atherosclerosis of Extremities

Inflammation

Study ID

NCT04774159

Start date

May 6, 2021

Status verified date

Mar, 2026

Completion date

Dec, 2029

Anticipated

Primary completion date

Dec, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion criteria:

1. Age > 18 years
2. Symptomatic atherosclerotic LE PAD fulfilling at least one of the following:

a. Intermittent claudication with ankle/arm blood pressure ratio\* (ABI ≤ 0.90) or artery stenosis ≥ 50% plus one of i. >1 vascular bed affected by atherosclerosis ii. Diabetes iii. Heart failure iv. Chronic kidney disease (eGFR < 60 mL/min/1.73 m2)

b. Rest pain (mostly in foot) OR necrosis of limb OR gangrene of limb (corresponding to either Fontaine stages 3 or 4 OR Rutherford Classification categories 4 to 6). All must have an ankle/arm blood pressure ratio\* (ABI ≤ 0.90) OR artery stenosis ≥ 50%.

\* In cases of incompressible ankle arteries, the presence of toe pressure ≤ 60 mm Hg or toe-brachial index ≤ 0.70 is acceptable

c. Revascularization defined as limb bypass surgery or endovascular revascularization procedures (irrespective of the specific device used), including percutaneous transluminal angioplasty/stent of iliac or infra-inguinal arteries or extra-anatomical bypass surgery

d. Leg or foot amputation for arterial vascular indications
3. Written or verbal informed consent from the patient

Exclusion Criteria:

1. Contraindication to colchicine
2. Long term requirement for colchicine for another clinical indication
3. Active diarrhoea
4. eGFR < 30 mL/min/1.73 m2
5. Cirrhosis or severe chronic liver disease
6. Woman who is pregnant, or breast-feeding or of child-bearing potential not protected by reliable contraception or is planning conception during the study
7. Current or planned long term use of cyclosporine, verapamil, HIV protease inhibitors, azole antifungals, or macrolide antibiotics (with the exception of azithromycin)
8. Patients who are deemed unlikely to return for follow-up
9. Patients with life expectancy < 1 year

Study Design

Enrollment

6150 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: Colchicine

Colchicine 0.5mg daily for the duration of the trial

placebo comparator: Colchicine-Placebo

Colchicine-Placebo daily

Interventions

Colchicine 0.5 MG Oral Tablet

Colchicine 0.5 mg tablet daily

Active drug and placebo are of the same appearance and are indistinguishable. All investigators, study personnel and patients will be blinded to drug treatment assignment. Trial treatment supplies must be stored in a secure, limited-access location under the storage conditions specified on the IP supply label.

Colchicine-Placebo

Colchicine-Placebo tablet

Primary outcome measure

  • Major adverse cardiovascular and limb events (MACE or MALE) [ Time Frame: 3-5 years ]

Central Contacts and Locations

Central contacts

Locations

Yale School of Medicine

Recruiting

New Haven, Connecticut, United States, 06511

Principal Investigator:

Carlos Mena-Hurtado, MD

University of Florida - Gainesville

Recruiting

Gainesville, Florida, United States, 32611

Principal Investigator:

Samir Shah, MD

Tampa General Hospital

Recruiting

Tampa, Florida, United States, 33606

Principal Investigator:

Sashi Inkollu, MD

University of Chicago Medical Center

Recruiting

Chicago, Illinois, United States, 60615

Principal Investigator:

Trissa Babrowski, MD

Henry Ford Health System

Recruiting

Detroit, Michigan, United States, 48202

Principal Investigator:

Tamer Boules, MD

Mayo Clinic

Recruiting

Rochester, Minnesota, United States, 55905

Principal Investigator:

Stanislav Henkin, MD

Rutgers University

Recruiting

Newark, New Jersey, United States, 07103

Principal Investigator:

Karim Salem, MD

University of North Carolina at Chapel Hill

Recruiting

Chapel Hill, North Carolina, United States, 27599

Principal Investigator:

Katharine McGinigle, MD

Duke Regional Hospital

Recruiting

Durham, North Carolina, United States, 27704

Principal Investigator:

Jennifer Rymer, MD

Duke University Medical Center

Recruiting

Durham, North Carolina, United States, 27710

Principal Investigator:

Jennifer Rymer, MD

Duke Raleigh Hospital

Recruiting

Raleigh, North Carolina, United States, 27609

Principal Investigator:

Jennifer Rymer, MD

Ohio State University Wexner Medical Center

Recruiting

Columbus, Ohio, United States, 43210

Principal Investigator:

Jake Hemingway, MD

Vanderbilt University Medical Center

Recruiting

Nashville, Tennessee, United States, 37232

Principal Investigator:

Aaron Aday, MD

Southwest Family Medicine

Recruiting

Dallas, Texas, United States, 75235

Principal Investigator:

Chrisette Dharma, MD

University of Texas Southwestern Medical Center

Recruiting

Dallas, Texas, United States, 75390

Principal Investigator:

Josh Beckman, MD

Texas Tech University Health Sciences

Recruiting

Lubbock, Texas, United States, 79430

Principal Investigator:

Debarata Mukherjee, MD

Sentara Norfolk General Hospital

Recruiting

Norfolk, Virginia, United States, 23507

Principal Investigator:

David Dexter, MD

University of Washington Medical Center

Recruiting

Seattle, Washington, United States, 98195

Principal Investigator:

Jake Hemingway, MD

Medical College of Wisconsin

Recruiting

Milwaukee, Wisconsin, United States, 53226

Principal Investigator:

Mitchell Dyer, MD

University of Calgary, Peter Lougheed Centre Vascular Clinic

Recruiting

Calgary, Alberta, Canada

Principal Investigator:

Caleb Zavitz, MD

University of Alberta, Mazankowski Heart Institute

Recruiting

Edmonton, Alberta, Canada

Principal Investigator:

Robert Welsh, MD

Hamilton General Hospital

Recruiting

Hamilton, Ontario, Canada, L8L 2X2

Contacts

Michelle Zondag

905-527-4322

Principal Investigator:

Noel Chan, MD

London Health Sciences Centre

Recruiting

London, Ontario, Canada

Principal Investigator:

Adam Power, MD

Vascular Health Bronte

Recruiting

Oakville, Ontario, Canada

Principal Investigator:

Beverley Chan, MD

Corcare Cardiovascular Research Inc.

Recruiting

Scarborough Village, Ontario, Canada

Principal Investigator:

Alan Joseph Ricci, MD

Niagara Health System

Recruiting

St. Catharines, Ontario, Canada

Principal Investigator:

Blair Leonard, MD

Sunnybrook Research Institute

Recruiting

Toronto, Ontario, Canada

Principal Investigator:

Ahmed Kayssi, MD

Toronto General Hospital

Recruiting

Toronto, Ontario, Canada

Principal Investigator:

Graham Roche-Nagle, MD

CIUSSS du Nord-de-l'île-de-Montréal, Hôpital du Sacré-Cœur-de-Montréal

Recruiting

Montreal, Quebec, Canada

Principal Investigator:

William Fortin, MD

Centre intégré de santé et de services sociaux du Bas-Saint-Laurent

Recruiting

Rimouski, Quebec, Canada, G5L 3N2

Principal Investigator:

François Caron, MD

More Information

Sponsor

Population Health Research Institute

Last update posted

Mar 24, 2026

Last verified

Mar, 2026

Keywords

  • Acute limb ischemia
  • Myocardial Infarction
  • Stroke
  • Cardiovascular death
  • Mortality

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Population Health Research Institute on 2026-03-24.